Adverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?
Recent research into liver disease indicates that muscle health is often compromised in its later stages.
Pathophysiology Articles
Explore articles focused on the pathophysiology of NASH. Gain a deeper understanding of the disease processes, from risk factors and progression to potential treatment targets.
Read MoreAdverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?
Dysregulations in Gut Microbiota Composition and Hepatic DNA Methylation in NAFLD: Is There a Link?
Patients with non-alcoholic fatty liver disease (NAFLD) exhibit alterations in their gut microbiota composition. Indeed, both nuclear and mitochondrial DNA methylation have been linked to the development of NAFLD and metabolic diseases, including obesity and type 2 diabetes mellitus.
From NAFLD to NASH: Determining Disease Progression and Regression Rates
The spectrum of non-alcoholic fatty liver disease (NAFLD) is divisible into three stages: 1) NAFL, 2) non-alcoholic steatohepatitis (NASH), NAFLD’s progressive and inflammatory subtype, and 3) NAFLD or NASH with fibrosis, whose stages range from F0-4.
Phospholipid Depletion and NAFLD Pathophysiology: Findings from Lipidomics
Along with its association with metabolic syndrome, NAFLD is closely linked with mixed dyslipidaemia (reduced high-density lipoprotein cholesterol (HDL-C) and increased very low-density lipoprotein triglycerides (VLDL-TG)).
T2D-Related Complications and its Impact on Fibrosis Levels: An Emerging Association?
Patients with T2D complications have a 4.5x greater risk of developing fibrosis, independent of HbA1c levels. FIB-4 index can help identify diabetic patients at highest risk, improving primary care screening.
Fatty Liver Disease: A Key Predictor of Cardiac Dysfunction and Remodelling?
Fatty liver disease (FLD) is found to be the strongest independent predictor of increased heart rate and reduced left ventricular volumes, and positively predicts cardiac remodelling
Non-Invasive Tests to Stratify NAFLD Based on Liver-Related Events: A Review
FIB4 and VCTE show promise in predicting prognosis for NAFLD patients. These non-invasive tests offer an alternative to liver biopsies for risk stratification. Quick and easily prescribed, they can streamline referrals and specialized management. A sequential algorithm with FIB4 and VCTE may improve NAFLD care.
Inflammation in Non-alcoholic Fatty Liver Disease: Part 1
Non-alcoholic fatty liver disease (NAFLD) has a more progressive form, non-alcoholic steatohepatitis (NASH). In both conditions, inflammation is a key driver of the pathogenesis. There are various causes of metabolic injury in the conditions, leading to the activation of different immune cells such as hepatic Kupffer cells.
Inflammation in Non-alcoholic Fatty Liver Disease: Part 2
Non-alcoholic fatty liver disease (NAFLD) has a more progressive form, non-alcoholic steatohepatitis (NASH). In both conditions, inflammation is a key driver of the pathogenesis. Current treatments mostly focus on promoting weight loss (through encouraging lifestyle changes, or, if necessary, bariatric surgery) and improving comorbidities through pharmacotherapy, such as type 2 diabetes.
MAFLD: brain-gut-liver axis and insulin resistance
There are many complex physio-pathologic connections within the brain, gut, and liver axis. This review by E. Rebelos et al. (University of Turku, Finland) is focused on the early pathophysiology of brain, gut, and liver axis in the context of insulin resistance and specifically addresses two pillars of hepatic insulin resistance....
Genetic and epigenetic factors determining NAFLD risk
Predicting the individual risk of NAFLD and determining the probability of disease progression is the basis for further developing prevention and treatment strategies. This requires knowledge of the genetic and epigenetic modifiers of NAFLD for genotype-guided risk stratification...
Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation
Xanthine oxidoreductase is an enzyme that catalyses hypoxanthine to xanthine and xanthine to uric acid, respectively. However, the underlying mechanisms of increased plasma xanthine oxidoreductase and its pathological roles in systemic diseases, such as atherosclerosis, are not fully understood...